Analyst Price Targets — RGNX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 25, 2026 3:31 pm | Yi Chen | H.C. Wainwright | $21.00 | $8.80 | TheFly | Regenxbio price target lowered to $21 from $23 at H.C. Wainwright |
| August 25, 2026 10:22 am | Brian Skorney | Robert W. Baird | $29.00 | $8.39 | TheFly | Regenxbio price target lowered to $29 from $32 at Baird |
| August 10, 2026 10:15 am | — | H.C. Wainwright | $23.00 | $10.72 | TheFly | Regenxbio price target lowered to $23 from $26 at H.C. Wainwright |
| August 7, 2026 1:48 pm | Judah Frommer | Morgan Stanley | $18.00 | $10.49 | TheFly | Regenxbio price target raised to $18 from $16 at Morgan Stanley |
| July 1, 2026 11:00 am | Yi Chen | H.C. Wainwright | $26.00 | $11.98 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX) |
| June 22, 2026 2:21 pm | Mani Foroohar | Leerink Partners | $18.00 | $8.88 | StreetInsider | Regenxbio Inc. (RGNX) PT Raised to $18 at Leerink |
| June 22, 2026 1:50 pm | Brian Skorney | Robert W. Baird | $32.00 | $8.91 | StreetInsider | Regenxbio Inc. (RGNX) PT Raised to $32 at Baird |
| May 15, 2026 12:29 pm | — | Morgan Stanley | $16.00 | $6.31 | TheFly | Regenxbio price target lowered to $16 from $17 at Morgan Stanley |
| May 15, 2026 9:00 am | Eliana Merle | Barclays | $12.00 | $6.25 | TheFly | Regenxbio price target lowered to $12 from $37 at Barclays |
| March 9, 2026 10:13 am | — | H.C. Wainwright | $30.00 | $10.38 | TheFly | Regenxbio price target lowered to $30 from $32 at H.C. Wainwright |
Latest News for RGNX
Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against certain of its offi
SAN DIEGO--(BUSINESS WIRE)---- $RGNX #BiotechInvesting--Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against certain of its officers and directors for alleged breaches of fiduciary duty. Shareholders who have held REGENXBIO shares continuously since prior to February 9, 2022, may have standing to seek corporate governance…
REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.
Regenxbio is rated a 'risky buy' due to high volatility, regulatory setbacks, and significant near-term catalysts. RGNX faces a clinical hold on RGX-121 for Hunter Syndrome, complicating milestone payments and royalty streams, but maintains sufficient cash runway into Q4 2027. Pivotal data for the AbbVie-partnered eye disease program and BLA submission for RGX-202 in DMD represent major binary catalysts by year-end…
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli PR Newswire ROCKVILLE, Md., Aug. 25, 20
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RGNX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.